IL134086A0 - Novel spiroazabicyclic heterocyclic compounds - Google Patents

Novel spiroazabicyclic heterocyclic compounds

Info

Publication number
IL134086A0
IL134086A0 IL13408698A IL13408698A IL134086A0 IL 134086 A0 IL134086 A0 IL 134086A0 IL 13408698 A IL13408698 A IL 13408698A IL 13408698 A IL13408698 A IL 13408698A IL 134086 A0 IL134086 A0 IL 134086A0
Authority
IL
Israel
Prior art keywords
heterocyclic compounds
novel
spiroazabicyclic heterocyclic
novel spiroazabicyclic
compounds
Prior art date
Application number
IL13408698A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9702746A external-priority patent/SE9702746D0/xx
Priority claimed from SE9800977A external-priority patent/SE9800977D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of IL134086A0 publication Critical patent/IL134086A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13408698A 1997-07-18 1998-07-10 Novel spiroazabicyclic heterocyclic compounds IL134086A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702746A SE9702746D0 (sv) 1997-07-18 1997-07-18 New compounds
SE9800977A SE9800977D0 (sv) 1998-03-24 1998-03-24 New compounds
PCT/SE1998/001364 WO1999003859A1 (en) 1997-07-18 1998-07-10 Novel spiroazabicyclic heterocyclic compounds

Publications (1)

Publication Number Publication Date
IL134086A0 true IL134086A0 (en) 2001-04-30

Family

ID=26663041

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13408698A IL134086A0 (en) 1997-07-18 1998-07-10 Novel spiroazabicyclic heterocyclic compounds
IL134086A IL134086A (en) 1997-07-18 2000-01-17 Spiro[1-azabicycloalkane furopyridine] and analogous compounds, their preparation and pharmaceutical compositions containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL134086A IL134086A (en) 1997-07-18 2000-01-17 Spiro[1-azabicycloalkane furopyridine] and analogous compounds, their preparation and pharmaceutical compositions containing them

Country Status (31)

Country Link
US (6) US6110914A (is)
EP (2) EP1213291B1 (is)
JP (1) JP2001510194A (is)
KR (1) KR100560036B1 (is)
CN (1) CN1117755C (is)
AR (2) AR013184A1 (is)
AT (2) ATE225792T1 (is)
AU (1) AU739022B2 (is)
BR (1) BR9810924A (is)
CA (1) CA2296031C (is)
DE (2) DE69827977T2 (is)
DK (1) DK0996622T3 (is)
EE (1) EE04399B1 (is)
ES (2) ES2231599T3 (is)
HK (3) HK1025322A1 (is)
HU (1) HUP0003844A3 (is)
ID (1) ID25548A (is)
IL (2) IL134086A0 (is)
IS (2) IS2027B (is)
MY (1) MY116761A (is)
NO (1) NO325324B1 (is)
NZ (1) NZ502298A (is)
PL (1) PL193065B1 (is)
PT (1) PT996622E (is)
RU (1) RU2202553C2 (is)
SA (1) SA98190668B1 (is)
SI (1) SI0996622T1 (is)
SK (1) SK283484B6 (is)
TR (1) TR200000129T2 (is)
TW (1) TW515799B (is)
WO (1) WO1999003859A1 (is)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500643A (en) 1997-05-30 2001-12-21 Neurosearch As Spiro-quinuclidine derivatives and their use in treating conditions responsive to nicotinic ACh receptor modulators
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6277870B1 (en) * 1998-05-04 2001-08-21 Astra Ab Use
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
TWI298068B (en) * 2000-06-21 2008-06-21 Dainippon Sumitomo Pharma Co Pharmaceutical composition for schizophrenia
ATE353332T1 (de) * 2001-06-01 2007-02-15 Astrazeneca Ab Neuer, für die therapie geeigneter ligand für nikotinische acetylcholinrezeptoren
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
JP2005510482A (ja) * 2001-10-16 2005-04-21 アストラゼネカ・アクチエボラーグ 線維筋痛症候群の治療方法
PL374384A1 (en) 2001-12-14 2005-10-17 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
CA2482313A1 (en) * 2002-04-18 2003-10-23 Astrazeneca Ab Heterocyclic compounds
US7417049B2 (en) * 2002-04-18 2008-08-26 Astrazeneca Ab Furyl compounds
WO2003087103A1 (en) 2002-04-18 2003-10-23 Astrazeneca Ab Thienyl compounds
ES2294330T3 (es) 2002-08-02 2008-04-01 MERCK & CO., INC. Derivados de furo(2,3-b)piridina sustituidos.
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
EP2062595A1 (en) * 2002-12-06 2009-05-27 The Feinstein Institute for Medical Research Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
JP4598674B2 (ja) * 2003-01-08 2010-12-15 田辺三菱製薬株式会社 統合失調症治療剤
US20050129610A1 (en) * 2003-06-24 2005-06-16 Johns Hopkins University Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor
AU2004276061A1 (en) 2003-09-25 2005-04-07 Astrazeneca Ab Ligands
AU2004282201A1 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
BRPI0415546A (pt) * 2003-10-21 2006-12-26 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
AU2005225458B2 (en) * 2004-03-25 2008-12-04 The Feinstein Institutes For Medical Research Neural tourniquet
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
EP1802258A4 (en) 2004-09-13 2015-09-23 Chrono Therapeutics Inc BIOSYNCHRONE TRANSDERMAL MEDICINES
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CN101124012B (zh) 2004-12-27 2012-09-05 范因斯坦医学研究院 通过电刺激迷走神经治疗炎症性疾病的装置
DE602006017235D1 (de) 2005-08-22 2010-11-11 Targacept Inc Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
US20080242688A1 (en) * 2007-03-19 2008-10-02 Astrazeneca Ab Method 741
GB2448224B (en) 2007-04-02 2010-09-01 Parkinson S Inst Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US8114891B2 (en) 2007-10-01 2012-02-14 Comentis, Inc. 4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof
NZ587312A (en) 2008-02-13 2011-12-22 Targacept Inc Combination of alpha 7 nicotinic agonists and antipsychotics
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
NZ590616A (en) 2008-06-20 2012-09-28 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
WO2010059617A2 (en) 2008-11-18 2010-05-27 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8886339B2 (en) 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
JP6095368B2 (ja) 2009-10-27 2017-03-15 ユセベ ファルマ ソシエテ アノニム 機能改変するＮａｖ１．７抗体
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
AU2010336337B2 (en) 2009-12-23 2016-02-04 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
WO2011116282A2 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nicotinic acetylcholine receptor agonists
PL3029039T3 (pl) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu
WO2012154865A2 (en) 2011-05-09 2012-11-15 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
RU2455306C1 (ru) * 2011-05-19 2012-07-10 Государственное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 3',4',5,6-ТЕТРАГИДРО-1Н-СПИРО[ПИРИДИН-4,5'-ТИЕНО[2,3-d]ПИРИМИДИНОВ]
BR112013032044A2 (pt) 2011-06-30 2016-12-13 Toray Industries antiprurítico
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
US8893339B2 (en) 2013-03-14 2014-11-25 Select Comfort Corporation System and method for adjusting settings of a bed with a remote control
WO2014202999A1 (en) 2013-06-21 2014-12-24 Takeda Cambridge Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TW201617342A (zh) 2014-07-11 2016-05-16 阿法馬根公司 調節α７活性之啶類
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127758A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
EP3668402A4 (en) 2017-08-14 2021-05-19 Setpoint Medical Corporation VAGUS NERVOUS STIMULATION PRE-SCREENING TEST
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems
EP3856180A1 (en) * 2018-09-24 2021-08-04 Astrazeneca AB Azd0328 dosage regime for treating cognitive impairment
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들
CN115340736B (zh) * 2022-05-20 2023-09-29 扬州实嘉电缆材料有限公司 一种氮磷阻燃剂改性聚氯乙烯防火电缆料

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681363A (en) * 1970-08-20 1972-08-01 Univ Temple Spiro(imidazolidine-4,3{40 -quinuclidine)-2,5-diones
JP3708962B2 (ja) * 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
US5468875A (en) * 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives
JP4176147B2 (ja) * 1995-07-28 2008-11-05 アボツト・ラボラトリーズ 化学的シナプス伝達の制御に有用なフロピリジン、チエノピリジン、ピロロピリジンおよび関連するピリミジン、ピリダジンおよびトリアジン化合物
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis

Also Published As

Publication number Publication date
AR013184A1 (es) 2000-12-13
KR20010021961A (is) 2001-03-15
BR9810924A (pt) 2000-08-15
DE69808631T2 (de) 2003-06-12
HUP0003844A2 (hu) 2001-07-30
PL193065B1 (pl) 2007-01-31
RU2202553C2 (ru) 2003-04-20
AU739022B2 (en) 2001-10-04
IS2027B (is) 2005-08-15
HK1031382A1 (en) 2001-06-15
US20030166935A1 (en) 2003-09-04
US20020187994A1 (en) 2002-12-12
SK283484B6 (sk) 2003-08-05
CN1270592A (zh) 2000-10-18
PL338259A1 (en) 2000-10-09
IS5338A (is) 2000-01-13
DE69808631D1 (de) 2002-11-14
CA2296031C (en) 2008-01-08
SA98190668B1 (ar) 2006-09-25
HK1046274B (zh) 2005-05-20
NO20000226D0 (no) 2000-01-17
AU8367998A (en) 1999-02-10
EP0996622B1 (en) 2002-10-09
US7507744B2 (en) 2009-03-24
JP2001510194A (ja) 2001-07-31
HK1025322A1 (en) 2000-11-10
CN1117755C (zh) 2003-08-13
MY116761A (en) 2004-03-31
DE69827977D1 (de) 2005-01-05
US6706878B2 (en) 2004-03-16
DE69827977T2 (de) 2005-12-08
PT996622E (pt) 2003-01-31
ES2185185T3 (es) 2003-04-16
IS7747A (is) 2005-03-16
EP1213291A1 (en) 2002-06-12
TR200000129T2 (tr) 2000-07-21
AR068013A2 (es) 2009-10-28
ATE225792T1 (de) 2002-10-15
EE200000031A (et) 2000-10-16
CA2296031A1 (en) 1999-01-28
ID25548A (id) 2000-10-12
US6110914A (en) 2000-08-29
DK0996622T3 (da) 2002-12-30
US20050004099A1 (en) 2005-01-06
US6703502B2 (en) 2004-03-09
US20080153864A1 (en) 2008-06-26
NO20000226L (no) 2000-03-14
SI0996622T1 (en) 2003-04-30
IL134086A (en) 2007-08-19
NO325324B1 (no) 2008-03-31
IS2434B (is) 2008-10-15
EP0996622A1 (en) 2000-05-03
ATE283859T1 (de) 2004-12-15
KR100560036B1 (ko) 2006-03-13
ES2231599T3 (es) 2005-05-16
EE04399B1 (et) 2004-12-15
EP1213291B1 (en) 2004-12-01
SK183599A3 (en) 2000-08-14
NZ502298A (en) 2002-02-01
US6369224B1 (en) 2002-04-09
HK1046274A1 (en) 2003-01-03
TW515799B (en) 2003-01-01
WO1999003859A1 (en) 1999-01-28
HUP0003844A3 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
IL134086A0 (en) Novel spiroazabicyclic heterocyclic compounds
EG24041A (en) New heterocyclic compounds
IL132170A0 (en) Novel heterocyclic compounds
GB9715892D0 (en) Heterocyclic compounds
GB9602294D0 (en) Heterocyclic compounds
GB9617305D0 (en) Heterocyclic compounds
AU7907498A (en) Novel heterocyclic compounds
AU7907298A (en) Novel heterocyclic compounds
ZA981920B (en) Novel heterocyclic compounds
GB9706294D0 (en) Heterocyclic compound
GB9707830D0 (en) Novel compounds
AUPO527597A0 (en) Novel heterocyclic compounds
ZA985448B (en) Novel heterocyclic compounds
ZA983800B (en) Novel heterocyclic compounds
EP0900204A4 (en) HETEROCYCLIC CONNECTIONS
ZA985449B (en) Novel heterocyclic compounds
EP0900217A4 (en) HETEROCYCLIC COMPOUNDS
EP0900219A4 (en) HETEROCYCLIC COMPOUNDS
EP0912183A4 (en) HETEROCYCLIC COMPOSITIONS
GB9719237D0 (en) Heterocyclic compounds
GB9715735D0 (en) Heterocyclic compounds
GB9716378D0 (en) Heterocyclic compounds
GB9801058D0 (en) Heterocyclic compounds
ZA981177B (en) Heterocyclic compounds
ZA989421B (en) Heterocyclic compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed